Skip to main content
    T

    TG Therapeutics Inc (TGTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $62.71
    -0.05 (-0.08%)

    Market Cap: $9.49B

    Last updated: Nov 17, 2026 at 4:41 PM ET

    TG Therapeutics Inc (TGTX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    TG Therapeutics (TGTX) has a market cap of $9.49B and an enterprise value of $9.75B. Revenue grew 76.08% over the last 12 months from the 12 months before. It kept 55.22% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 2.77% above the market cap, as debt exceeds cash.

    Market Cap$9.49B
    Enterprise Value$9.75B
    Latest price (Nov 17, 2026)$62.71

    Key Dates

    The next earnings report is expected on Jan 11, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateJan 11, 2027 (expected)
    Last Earnings DateNov 9, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 1.85% in the quarter ended Jun 30, 2026 and shrank 1.03% a year over 2 years.

    Shares Outstanding141.77M
    Shares Change (YoY)-3.39%
    Shares Change (QoQ)-1.85%
    Share Count Growth (2Y CAGR)-1.03%

    Valuation Ratios

    Sales and book value multiples are 11.1x and 14.7x.

    P/E Ratio87.1x
    Forward P/E61.2x
    P/S Ratio11.1x
    Forward P/S9.5x
    P/B Ratio14.7x
    P/FCF Ratio511.4x
    P/OCF Ratio530.7x
    PEG Ratio8.4

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 61.9x EBITDA and 526.5x free cash flow.

    EV / Earnings22.1x
    EV / Sales12.2x
    EV / EBITDA61.9x
    EV / EBIT65.8x
    EV / FCF526.5x

    Price Statistics

    The stock is up 102.29% over 52 weeks and trades 10.08% above its 50-day average.

    Beta (1Y)0.70
    52-Week Change+102.29%
    1-Month Change+17.65%
    3-Month Change+21.32%
    6-Month Change+59.04%
    5-Year Change+95.96%
    10-Year Change+1043.55%
    Total Return (1Y)+102.29%
    Total Return (3Y CAGR)+73.18%
    Total Return (5Y CAGR)+20.34%
    Return vs SPY (1Y)+89.37%
    Max Drawdown (1Y)-21.83%
    Max Drawdown (3Y)-42.01%
    Sharpe Ratio (1Y)1.54
    Correlation with SPY (1Y)0.21
    50-Day Average$56.97
    200-Day Average$45.71
    52-Week Range$26.76 to $68.03
    RSI (14 Days)59.2
    Average Volume (20 Days)2.14M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.27x current liabilities, and total debt is 1.23x shareholder equity.

    Current Ratio4.27x
    Quick Ratio3.72x
    Debt / Equity1.23x
    Debt / EBITDA5.04x
    Debt / FCF42.88x
    Interest Coverage3.18x

    Returns and Efficiency

    Return on invested capital is 10.99% over the last 12 months, against a 5-year average of -36.86%.

    Return on Equity (ROE)73.08%
    Return on Assets (ROA)26.93%
    Return on Invested Capital (ROIC)10.99%
    Return on Capital Employed (ROCE)10.81%
    ROE (5Y Average)-88.28%
    ROA (5Y Average)-31.47%
    ROIC (5Y Average)-36.86%
    Asset Turnover0.68x
    Inventory Turnover1.02x
    Receivables Turnover2.01x
    Cash Conversion Cycle70 days

    Scores

    TGTX has an Altman Z-Score of 5.68, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score5.68
    Altman Z ZoneSafe
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $799.54M over the last 12 months.

    Revenue$799.54M
    Revenue Growth (YoY)+76.08%
    Gross Profit$658.60M
    Operating Income$136.33M
    Pretax Income$101.60M
    Net Income$441.49M
    EBITDA$147.90M
    EBIT$148.24M
    Reported EPS (TTM)$0.72

    Trailing 12 months through Jun 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 36.83% of the $1.64B in total assets.

    Cash and Equivalents$482.57M
    Total Debt$745.39M
    Net Debt$262.81M
    Net Debt Per Share$1.85
    Working Capital$877.19M
    Shareholder Equity$604.08M
    Book Value Per Share$4.26
    Total Assets$1.64B
    Total Liabilities$1.04B

    Balance sheet as of Jun 30, 2026.

    Full balance sheet

    Cash Flow

    After $491.00K of capital spending, operating cash flow left $17.39M of free cash flow.

    Operating Cash Flow$17.88M
    Capital Expenditures$491.00K
    Free Cash Flow$17.39M
    FCF Per Share$0.11
    Depreciation and Amortization$663.00K

    Trailing 12 months through Jun 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 17.05%.

    Gross Margin82.37%
    Operating Margin17.05%
    Pretax Margin12.71%
    Net Margin55.22%
    EBITDA Margin18.50%
    EBIT Margin18.54%
    FCF Margin2.17%
    Gross Margin (5Y Average)90.82%

    Growth

    Revenue grew 504.86% a year over 3 years.

    Revenue Growth (3Y CAGR)+504.86%
    Revenue Growth (5Y CAGR)+426.73%
    Book Value Per Share Growth (2Y CAGR)+90.40%
    Tangible Book Per Share Growth (2Y CAGR)+90.40%

    Revenue and profit by year

    Dividends and Yields

    TGTX does not pay a dividend. Its free cash flow yield is 0.20%.

    Earnings Yield1.15%
    FCF Yield0.20%
    Buyback Yield2.00%
    Shareholder Yield2.00%

    Stock Splits

    The last split was a 1-for-56 reverse split on Apr 30, 2012.

    Last Split DateApr 30, 2012
    Split TypeReverse split
    Split Ratio1:56

    Peer Position

    Against 3 similar companies, TGTX has the highest P/E.

    P/E Ratio87.1x vs 39.5x median
    P/S Ratio11.1x vs 8.8x median
    ROIC10.99% vs -21.06% median
    Revenue Growth (Trailing 4 Quarters, YoY)+76.08% vs +37.67% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 47.69% and EPS growth at 125.98% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+47.69%
    EPS Growth Forecast (2Y CAGR)+125.98%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About TGTX

    What is TGTX's market cap?

    TG Therapeutics has a market cap of $9.49B. Its enterprise value, which adds debt and subtracts cash, is $9.75B.

    What is TGTX's P/E ratio?

    TG Therapeutics has a trailing P/E ratio of 87.1x and a forward P/E of 61.2x.

    How many shares of TGTX are outstanding?

    TG Therapeutics has 141.77M shares outstanding. The count is down 3.39% from a year earlier.

    Does TGTX pay a dividend?

    No. TG Therapeutics does not pay a dividend.

    How much debt does TGTX have?

    TG Therapeutics has $745.39M of total debt and $482.57M of cash and equivalents, a net debt position of $262.81M.